The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against HIV-1 gp120 envelope (...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Karasavvas, Nicos, Billings, Erik, Rao, Mangala, Williams, Constance, Zolla-Pazner, Susan, Bailer, Robert T., Koup, Richard A., Madnote, Sirinan, Arworn, Duangnapa, Shen, Xiaoying, Tomaras, Georgia D., Currier, Jeffrey R., Jiang, Mike, Magaret, Craig, Andrews, Charla, Gottardo, Raphael, Gilbert, Peter, Cardozo, Timothy J., Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Paris, Robert, Greene, Kelli, Gao, Hongmei, Gurunathan, Sanjay, Tartaglia, Jim, Sinangil, Faruk, Korber, Bette T., Montefiori, David C., Mascola, John R., Robb, Merlin L., Haynes, Barton F., Ngauy, Viseth, Michael, Nelson L., Kim, Jerome H., de Souza, Mark S.
Format: Artigo
Jezik:Inglês
Izdano: Mary Ann Liebert, Inc. 2012
Teme:
Vaccines
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3484815/
https://ncbi.nlm.nih.gov/pubmed/23035746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2012.0103
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items